Article info
PDFCommentary
Changing TACTICS in intermediate HCC: TACE plus sorafenib
- Correspondence to Professor Jean-François Dufour, Hepatology, Department of Clinical Research, University of Bern, Bern 3010, Switzerland; jean-francois.dufour{at}dbmr.unibe.ch
Citation
Changing TACTICS in intermediate HCC: TACE plus sorafenib
Publication history
- Received January 16, 2020
- Revised February 24, 2020
- Accepted February 24, 2020
- First published March 13, 2020.
Online issue publication
July 07, 2020
Article Versions
- Previous version (13 March 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.